Aclaris Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying
Portfolio Pulse from Avi Kapoor
Insiders are buying shares of Aclaris Therapeutics, BranchOut Food, Innovative Food Holdings, and Crown Equity Holdings, indicating confidence in these companies. Notable transactions include significant purchases by directors and officers.
July 23, 2024 | 11:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aclaris Therapeutics' 10% owner Braden Michael Leonard acquired 154,722 shares at $1.31 each, spending around $201,808. This follows the sale of OLUMIANT royalties and milestones to OMERS Life Sciences for up to $31.5 million.
The insider purchase indicates strong confidence in Aclaris Therapeutics' future prospects, especially following a significant deal with OMERS Life Sciences.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
BranchOut Food Director Byron Riche Jones bought 41,755 shares at $0.99 each, spending around $41,337. This comes after the company announced a $1.4 million public offering.
The insider purchase suggests confidence in BranchOut Food's future, especially after the recent public offering.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Crown Equity Holdings Marketing/Merger/Acq. Officer Jamie Hadfield acquired 5,000 shares at $0.25 each, spending around $1,250. This follows the appointment of a new Chairman and Chief Strategic & Science Officer.
The insider purchase suggests confidence in the company's new leadership and strategic direction.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 100
POSITIVE IMPACT
Innovative Food Holdings Director Denver Johnson Smith acquired 350,000 shares at $1.20 each, spending around $420,000. This follows a 5.7% revenue decline in Q1.
The large insider purchase indicates confidence in the company's recovery and future growth despite recent revenue declines.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 100